Table 2.

Treatment-related adverse events by maximum grade per patient

Adverse Events	Grade 1	Grade 2	Grade 3	Grade 4
Hematological
Anemia*	9 (26%)	11 (31%)	11 (31%)	0
Decreased platelets	9 (26%)	0	0	0
Decreased leukocytes	7 (20%)	4 (11%)	1 (3%)	0
Decreased lymphocytes	4 (11%)	14 (40%)	7 (20%)	0
Decreased neutrophils	0	3 (9%)	1 (3%)	0
Gastrointestinal
Nausea	16 (46%)	1 (3%)	0	0
Vomit	12 (34%)	0	0	0
Diarrhea	8 (23%)	1 (3%)	0	0
Constipation	4 (11%)	0	0	0
GERD	5 (14%)	0	0	0
Anorexia	8 (23%)	1 (3%)	0	0
Proctitis	0	1 (3%)	0	0
Endocrinology and Chemistry
Hypothyroidism	1 (3%)	0	0	0
Hyperthyroidism	2 (6%)	0	0	0
Increased creatinine	7 (20%)	4 (11%)	0	0
Increased ALT/AST	3 (9%)	0	0	0
Dermatological
Rash	2 (6%)	1 (3%)	1 (3%)	0
Hyperpigmentation	2 (6%)	0	0	0
Erythema multiforme	1 (3%)	0	0	0
Other
Fatigue	14 (40%)	5 (14%)	0	0
Headache	2 (6%)	0	0	0
Insomnia	1 (3%)	0	0	0
Arthralgia	2 (6%)	0	0	0
Myalgia	1 (3%)	0	0	0
Weight loss	1 (3%)	0	0	0
Weight gain	1 (3%)	0	0	0
Dry eye	1 (3%)	0	0	0
Dry mouth	1 (3%)	0	0	0
Flushing**	1 (3%)	0	0	0

^*Three patients required olaparib dose reduction because of recurrent anemia. No one had durvalumab dose reduction or discontinuation due to adverse events. No treatment related deaths were recorded.

^**During durvalumab infusion

Abbreviations: GERD = gastroesophageal reflux disease, ALT = alanine aminotransferase, AST = aspartate aminotransferase